Physician profile
Mark Sherrid
NPI 1154314847
$97,083.22
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $30K · 2021: $17.65 · 2022: $6,013 · 2023: $17K · 2024: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $32K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $46.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $31,766.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,500.00 |
| Food and Beverage | $46.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion, INC. | $70,088.24 | 2019-2024 | |
| Pfizer INC. | $26,875.00 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $43.39 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $30.58 | 2021-2022 | |
| Amgen INC. | $25.21 | 2024 | Repatha |
| Irhythm Technologies, INC. | $20.80 | 2023 | Zio Xt Patch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sherrid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.